* All times shown in EST
8:00 am
Registration & Morning Coffee
8:50 am Chair’s Opening Remarks
Harnessing the Therapeutic Applications of Modified Exosomes Across Different Indications
9:00 am Novel Exosome-Based Therapies for Treating Colorectal Cancer
Synopsis
- T cells costimulatory functions are affected by tumor-intrinsic mechanism in colorectal cancer leading to host immune suppression
- Modified colorectal cancer tumor EVs without immune suppressive microRNAs can stimulate antitumor immunity and has therapeutic potential in advanced disease models
- Harnessing the immunogenicity of modified tumor EVs can be developed as a novel therapeutic strategy to reduce cancer immunotherapy resistance
9:30 am GMP Manufacturing for Exosome-Based Therapies
Synopsis
- The critical role of analytics and process development for clinical production
- An effective process for clinical manufacturing and beyond
10:00 am Diving into the Therapeutic Potential of Engineered Exosomes in Inflammatory Diseases & CNS Disorders
Synopsis
- Unlocking insights into moving from pre-clinical to clinical stages
- Leveraging exosomes for the treatment of inflammatory disease in organs including kidney and liver
- Exploring CNS targeting exosome: a new target technology to deliver exosomes to the CNS
10:30 am
Morning Break & Structured Networking
Track A: Discovery
Unravelling the Enhanced Therapeutic Values of Different Sources of EVs
11:30 am Unlocking the Therapeutic Potential of Cell- Derived Vesicles (CDVs)
Synopsis
- Enhanced therapeutic outcomes through targeted RNA cargo delivery
- Unravelling the ability of CDVs to overcome cellular and tissue barriers
- Unique advantages of CDVs to allow large-scale manufacturing
12:00 pm Cell Reprogramming & Regenerative Medicine Using Extracellular Vesicles
Synopsis
- Quantitative mass spectrometry in defining circulating EVs at proteome and lipidome levels
- How do EVs and specific regulatory cargo signal in target cells?
- Defining the EV surface as an interactive platform
- Strategies for dynamically reprogramming target cells and tissues
Track B: Translation
Progressing Pre-Clinical & Translational Applicability of EVs towards Clinical Development
11:30 am Maximizing the Therapeutic Potential of the SIRP-Exosome in Liver Diseases
Synopsis
- Maximizing the expression of potential therapeutic proteins on surface of exosomes through the maxisome platform technology
- Exploring applications of the SIRP-Exosomes in liver diseases
- Overcoming heterogeneous and complex liver diseases through the SIRP-Exosome
12:00 pm Exosome- Based Therapeutical Solution from “Right” Targets
Synopsis
- Development of triple negative breast cancer specific biomarker panel from patients
- What spell the “right” biomarker(s) for potential metastasis/recurrence
- Plan to the confirmation of functional biomarkers leading to the druggable targets
12:30 pm
Networking Lunch
Optimizing Production, Storage & Potency of EVs for Improved Bioactivity
1:30 pm Effects of Storage Conditions on EV Bioactivity & Loaded Cargo
Synopsis
- EVs can be loaded with cargo via a variety of endogenous and exogenous methods
- Storage time and temperature affect intrinsic EV bioactivity as well as the amount and activity of loaded cargo
- Lyophilization is a viable option for EV storage
2:00 pm Technological & Developmental Aspects of the Production of EVs from Allogeneic Bone Marrow-Derived MSCs
Synopsis
- Unraveling characterization approaches for EVs from allogeneic bone marrow-derived MSCs
- Exploring the protein profile of EVs from allogeneic bone marrow-derived MSCs and their impact on continuous wound healing
- Discuss potency assay development
- Potential data on new indication
Accelerating Late Stage Clinical Development of EVs & Progress Update
1:30 pm Advancement on Clinical Trials with Amniotic Fluid Extracellular Vesicles
Synopsis
- Novel source of Perinatal derived Extracellular Vesicles
- Phase I/II Clinical Trials Protocol
- Results of a completed Expanded Access Trial
2:00 pm EXO-CD24 (CovenD24) Promise in the Corona Age & Beyond – the Road from an Idea to a Groundbreaking Reality
Synopsis
- How we accelerated the route to clinical phases within 6 months of discovery and launched phase 3 in two years
- Unravelling the therapeutic potential of EXO-CD24 to treat the most important complication of COVID-19, the cytokine storm and reduce overreaction of the immune system
- Developing the next steroid- similar (or even better) efficacy without the AEs
2:30 pm
Afternoon Networking Break & Poster Session
Bioengineering Approaches for Effective Payload Manipulation & Cargo Loading
3:15 pm Panel Discussion: Comparing Engineered & Naturally Derived Exosomes for Therapeutic Benefit
Synopsis
- What are the advantages and limitations of engineering exosomes as therapeutics and as drug delivery vehicles?
- Linking engineering to the successful loading of cargo
4:15 pm Leveraging Bioengineering Approaches for Exosome-Based Precision Drug Delivery
Synopsis
- Identify key challenges in exosome-based drug delivery
- Introduce bioengineering solutions to exosome isolation, payload manipulation, and cargo loading
- Introduce cellular sources for EV production and molecular engineering